Literature DB >> 32345670

The Clinical Relevance of Frequent Germline Genetic Variants Detected by Targeted Sequencing in Patients With Rectal Adenocarcinoma (READ).

Kevin Chih-Yang Huang1,2, Shu-Fen Chiang3,4, Tao-Wei Ke5, William Tzu-Liang Chen5, Tsung-Wei Chen6,7, Kun-San Clifford Chao8.   

Abstract

BACKGROUND: The progression of colorectal cancer (CRC) mainly stems from the occurrence of somatic mutation. However, there is little information that can be used to comprehensively analyse the importance of germline variants in CRC patients. PATIENTS AND METHODS: The candidate germline variants between tumor relapse and cured rectal adenocarcinoma (READ) were firstly filtered by whole-exome sequencing (n=4), and validated by targeted sequencing and associated with clinical outcome in READ (n=48).
RESULTS: We identified 9 pathogenic germline variants that were clinically associated with survival outcome in READ, including TIPIN, TLR1, TLR10, OR4D6, IGSF3, UBBP4, OR6J1, FAM208A and DISC1. Patients carrying these germline susceptibility variants had an increased risk of poor survival outcome compared to those without these variants.
CONCLUSION: Not only the tumor genome, but also the germline sequence must be analysed to depict the overall genetic profile, providing potential therapeutic strategies for personalized medicine. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Targeted sequence panel; personalized medicine; rectal adenocarcinoma; whole exome sequence

Year:  2020        PMID: 32345670      PMCID: PMC7259889          DOI: 10.21873/cgp.20189

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  29 in total

1.  Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases.

Authors:  Emmanouil Pikoulis; Georgios A Margonis; Nikolaos Andreatos; Kazunari Sasaki; Anastasios Angelou; Georgios Polychronidis; Anastasia Pikouli; Elena Riza; Timothy M Pawlik; Efstathios Antoniou
Journal:  Anticancer Res       Date:  2016-09       Impact factor: 2.480

2.  Reevaluation of Preoperative Chemoradiotherapy for Clinical T3 Lower Rectal Cancer: A Multicenter Collaborative Retrospective Clinical Study.

Authors:  Mitsumasa Takeda; Hidejiro Kawahara; Masaichi Ogawa; Katsuhito Suwa; Ken Eto; Katsuhiko Yanaga
Journal:  Anticancer Res       Date:  2019-06       Impact factor: 2.480

3.  Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy.

Authors:  Chih-Yang Huang; Shu-Fen Chiang; Tao-Wei Ke; Tsung-Wei Chen; Yu-Ching Lan; Ying-Shu You; An-Cheng Shiau; William Tzu-Liang Chen; K S Clifford Chao
Journal:  Cancer Immunol Immunother       Date:  2017-12-21       Impact factor: 6.968

4.  Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.

Authors:  Tsung-Wei Chen; Kevin Chih-Yang Huang; Shu-Fen Chiang; William Tzu-Liang Chen; Tao-Wei Ke; K S Clifford Chao
Journal:  J Cancer Res Clin Oncol       Date:  2019-03-14       Impact factor: 4.553

5.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

6.  Identification of novel variants in colorectal cancer families by high-throughput exome sequencing.

Authors:  Melissa S DeRycke; Shanaka R Gunawardena; Sumit Middha; Yan W Asmann; Daniel J Schaid; Shannon K McDonnell; Shaun M Riska; Bruce W Eckloff; Julie M Cunningham; Brooke L Fridley; Daniel J Serie; William R Bamlet; Mine S Cicek; Mark A Jenkins; David J Duggan; Daniel Buchanan; Mark Clendenning; Robert W Haile; Michael O Woods; Steven N Gallinger; Graham Casey; John D Potter; Polly A Newcomb; Loïc Le Marchand; Noralane M Lindor; Stephen N Thibodeau; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-05-01       Impact factor: 4.254

7.  Prognostic Significance of Clinicopathological and Molecular Features After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.

Authors:  Hee Jeong Cho; Jin Ho Baek; Dong Won Baek; Byung Woog Kang; Soo Jung Lee; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu Seog Choi; Jong Gwang Kim
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

8.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.

Authors:  Steven M Teutsch; Linda A Bradley; Glenn E Palomaki; James E Haddow; Margaret Piper; Ned Calonge; W David Dotson; Michael P Douglas; Alfred O Berg
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

9.  Oncologic impact of pathologic response on clinical outcome after preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Wook Hyeon Yoon; Hun Jin Kim; Chang Hyun Kim; Jae Kyoon Joo; Young Jin Kim; Hyeong Rok Kim
Journal:  Ann Surg Treat Res       Date:  2014-12-26       Impact factor: 1.859

10.  Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer.

Authors:  Peng-Chan Lin; Yu-Min Yeh; Pei-Ying Wu; Keng-Fu Hsu; Jang-Yang Chang; Meng-Ru Shen
Journal:  Sci Rep       Date:  2019-03-08       Impact factor: 4.379

View more
  1 in total

1.  Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy.

Authors:  Kevin Chih-Yang Huang; Shu-Fen Chiang; Tsung-Wei Chen; William Tzu-Liang Chen; Pei-Chen Yang; Tao-Wei Ke; K S Clifford Chao
Journal:  Sci Rep       Date:  2020-12-18       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.